Nutriband Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $56.8M
- Price
- $4.67
- % Change (Daily % change from the live per-ticker quote feed.)
- +22.32%
- Volume
- 67.5K
About
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Quick stats
Shares outstanding12.2M
Computed float2.2M
Float / shares17.9%
Cash runway (months)8.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001676047
Websitehttps://nutriband.com
AI Summary
AI-generated1/8
minorneutralother
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
Nutriband announced that CEO Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on August 26 as part of the CEO spotlight event.
The summit brings together leaders from biotechnology, medical technology, and investment sectors to showcase innovation in Georgia's life sciences industry.
Nutriband focuses on transdermal pharmaceutical products, specifically its AVERSA abuse-deterrent technology designed to prevent abuse in patches like fentanyl.